| Name | Title | Contact Details |
|---|
San Diego FC is a Major League Soccer (MLS) expansion team set to begin play in 2025. Owned by Sir Mohamed Mansour through his family office, Man Capital, the club focuses on social impact, environmental sustainability, and youth development. It operates under the Right to Dream model, a globally recognized soccer academy system that emphasizes holistic athlete development and community engagement. The team will compete in MLS, with home games at Snapdragon Stadium. San Diego FC also features the Right to Dream Academy, which provides free education, housing, and soccer training to young athletes. This academy aims to foster athletic development, academic excellence, and personal growth, mirroring existing facilities in Ghana, Egypt, and Denmark. Additionally, the club engages in community programs that promote diversity and inclusion, targeting local residents and youth athletes from underserved communities. The ownership structure reflects a partnership between Mansour’s Man Capital and the Sycuan Tribe, blending global sports investment with local heritage.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Valent Partners are an integrated team of strategists, business leaders and technologists obsessed with helping our clients reach new heights. We approach each situation through a holistic business and technology lens, advising on and delivering solutions that help your organization adapt ahead of your competition. You have a goal. Well get you there. If your organization is interested in finding ways that technology can improve your performance, profitability, and growth, we can help. Contact Valent Partners today to arrange a consultation on the challenges you face. Your Digital Journey begins here.
Elements Room specializes in slab materials from all over the world both man-made and natural. Elements Room aims to be the first and single point of contact for premium surfaces throughout any project. The curated inventory features only the highest quality, trending surfaces. Created as a destination for designers, architects, and industry professionals looking to meet with clients outside of their home or office, the space provides the perfect combination of premium surface materials with comfortable, private work spaces and facilities. Superior materials on display include all types of natural stones, semi-precious, quartz and porcelain options.